AR045037A1 - Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. - Google Patents

Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.

Info

Publication number
AR045037A1
AR045037A1 ARP040102391A ARP040102391A AR045037A1 AR 045037 A1 AR045037 A1 AR 045037A1 AR P040102391 A ARP040102391 A AR P040102391A AR P040102391 A ARP040102391 A AR P040102391A AR 045037 A1 AR045037 A1 AR 045037A1
Authority
AR
Argentina
Prior art keywords
alkyl
heteroaryl
aryl
conh
heterocyclyl
Prior art date
Application number
ARP040102391A
Other languages
English (en)
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0308442A external-priority patent/FR2857363B1/fr
Priority claimed from FR0308441A external-priority patent/FR2857362B1/fr
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of AR045037A1 publication Critical patent/AR045037A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente se refiere principalmente a nuevas tetrahidro-1H-pirazolo[3,4-c]piridinas sustituidas que tienen una actividad terapéutica, utilizables en particular en oncología y composiciones que las contienen. Reivindicación 1: Producto de la fórmula general (1) siguiente, y sus tautómeros, caracterizado porque: L se elige entre enlace, -CH2, CO, SO2, CONH, COO, NHCO, NH, NHSO2, SO2NH, NHCONH, CH2NH y NHCH2; X se elige entre enlace, CH2, CO, SO2, CONH y COO; R1 se elige entre OH, H, alquilo, cicloalquilo, heterociclilo, arilo y heteroarilo, eventualmente sustituido y, cuando X es enlace, entonces R1 también puede ser halógeno; R2 es H o se elige entre alquilo, alquileno, cicloalquilo, heterociclilo, arilo y heteroarilo, eventualmente sustituido; y porque los sustituyentes se eligen independientemente entre R3, O-R3, halógeno, NO2, SO2-R3, CO-R3, SO2NH-R3, CONH-R3, N-(R3)2, NHCO-R3, NHSO2-R3, NHCONH-R3, NHSO2NH-R3, OCO-R3, COO-R3, OSO2-R3, SO2O-R3, OCONH-R3 y OSO2NH-R3, en el que cada R3 se elige independientemente entre H, alquilo, cicloalquilo, alquenilo, arilo, heteroarilo y heterociclilo, eventualmente sustituido con halógeno, arilo, heteroarilo, R4, OR4 y N(R4)2, en el que cada R4 se elige independientemente entre H, alquilo C1-4 y alquilo halogenado C1-4
ARP040102391A 2003-07-10 2004-07-07 Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion. AR045037A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0308442A FR2857363B1 (fr) 2003-07-10 2003-07-10 4,5,6,7-tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees compositions les contenant et utilisation
FR0308441A FR2857362B1 (fr) 2003-07-10 2003-07-10 Tetrahydro-1h-pyrazolo[3,4-c] pyridines substituees, compositions les contenant et utilisation

Publications (1)

Publication Number Publication Date
AR045037A1 true AR045037A1 (es) 2005-10-12

Family

ID=34081983

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102391A AR045037A1 (es) 2003-07-10 2004-07-07 Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.

Country Status (12)

Country Link
US (2) US7109340B2 (es)
EP (2) EP1646632A2 (es)
JP (1) JP4740841B2 (es)
KR (1) KR20060054291A (es)
AR (1) AR045037A1 (es)
AU (1) AU2004256945B2 (es)
BR (1) BRPI0412411A (es)
CA (1) CA2532122A1 (es)
IL (1) IL172994A0 (es)
MX (1) MXPA06000247A (es)
TW (1) TW200519110A (es)
WO (1) WO2005007653A2 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2888579A1 (fr) * 2005-07-13 2007-01-19 Aventis Pharma Sa Pyrazolo pyridines substituees, compositions les contenant, procede de fabrication et utilisation
CN101203224B (zh) * 2005-01-28 2010-11-03 诺瓦提斯公司 嘧啶基氨基苯甲酰胺在制备治疗对Tie-2激酶活性的调节有响应的疾病的药物中的用途
CN101160312A (zh) * 2005-04-14 2008-04-09 霍夫曼-拉罗奇有限公司 三环吡咯衍生物、它们的制备和作为药剂的应用
EP2001882A1 (en) * 2006-03-23 2008-12-17 F. Hoffmann-La Roche AG Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
WO2008060568A2 (en) * 2006-11-15 2008-05-22 Neurogen Corporation Amide-substituted aryl piperidines
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
IL289834B1 (en) 2012-06-13 2024-03-01 Incyte Holdings Corp Conversion of tricyclic compounds as FGFR inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
ES2666155T3 (es) 2013-03-14 2018-05-03 Janssen Pharmaceutica Nv Moduladores de P2X7
US9040534B2 (en) 2013-03-14 2015-05-26 Janssen Pharmaceutica Nv [1,2,4]triazolo[4,3-a]pyrazines as P2X7 modulators
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
TWI599567B (zh) 2013-03-14 2017-09-21 健生藥品公司 Ｐ２ｘ７調節劑
WO2014152018A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydrocyclopentapyrroles, their preparation and use
EP2968304B1 (en) 2013-03-14 2018-10-10 The Trustees of Columbia University in the City of New York 4-phenylpiperidines, their preparation and use
JO3509B1 (ar) 2013-03-14 2020-07-05 Janssen Pharmaceutica Nv معدلات p2x7
SG10201708520YA (en) 2013-04-19 2017-12-28 Incyte Corp Bicyclic heterocycles as fgfr inhibitors
CN106794364B (zh) 2014-04-30 2019-12-24 哥伦比亚大学董事会 取代的4-苯基哌啶及其制备和用途
EA034015B1 (ru) 2014-09-12 2019-12-19 Янссен Фармацевтика Нв Модуляторы р2х7
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MX2017010673A (es) 2015-02-20 2018-03-21 Incyte Corp Heterociclos biciclicos como inhibidores de receptores del factor de crecimiento fibroblastico (fgfr).
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
KR20210069080A (ko) 2018-09-28 2021-06-10 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 조절제
US20200102311A1 (en) 2018-09-28 2020-04-02 Janssen Pharmaceutica Nv Monoacylglycerol Lipase Modulators
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AU2020358948A1 (en) 2019-09-30 2022-05-26 Janssen Pharmaceutica Nv Radiolabelled MGL PET ligands
JP2022552324A (ja) 2019-10-14 2022-12-15 インサイト・コーポレイション Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11897891B2 (en) 2019-12-04 2024-02-13 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
BR112022010664A2 (pt) 2019-12-04 2022-08-16 Incyte Corp Derivados de um inibidor de fgfr
MX2022008665A (es) * 2020-01-13 2022-08-10 Aptabio Therapeutics Inc Nuevo derivado de pirazol.
CA3176946A1 (en) 2020-03-26 2021-09-30 Janssen Pharmaceutica Nv Monoacylglycerol lipase modulators
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT77517A (hu) * 1994-10-20 1998-05-28 Pfizer Inc. Biciklusos tetrahidro-pirazolo-piridin-származékok, alkalmazásuk és ilyen vegyületeket tartalmazó gyógyászati készítmények
US6391874B1 (en) 1996-07-13 2002-05-21 Smithkline Beecham Corporation Fused heterocyclic compounds as protein tyrosine kinase inhibitors
CA2283961A1 (en) 1997-03-19 1998-09-24 Basf Aktiengesellschaft Pyrrolo[2,3d]pyrimidines and their use as tyrosine kinase inhibitors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
CN1278724A (zh) 1997-10-06 2001-01-03 巴斯福股份公司 抑制酪氨酸激酶活性的茚并[1,2－c]吡唑衍生物
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
WO1999030710A1 (en) * 1997-12-13 1999-06-24 Bristol-Myers Squibb Company USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS
EP1071658B1 (en) 1998-04-17 2004-06-16 Parker Hughes Institute Btk inhibitors and methods for their identification and use
DE69918542T2 (de) 1998-04-30 2005-08-18 Abbott Gmbh & Co. Kg Substituierte trizyklische pyrazolderivate mit protein kinase aktivität
KR20010085822A (ko) 1998-09-18 2001-09-07 스타르크, 카르크 키나제 억제제로서의 4-아미노피롤로피리미딘
KR20010085824A (ko) 1998-09-18 2001-09-07 스타르크, 카르크 단백질 키나아제 억제제로서의 피롤로피리미딘
KR20010086005A (ko) 1998-11-06 2001-09-07 스타르크, 카르크 트리사이클릭 피라졸 유도체
CN1636005A (zh) 1999-06-03 2005-07-06 克诺尔股份有限公司 苯并噻嗪酮和苯并噁嗪酮化合物
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
DE60015594T2 (de) 1999-11-22 2005-10-27 Smithkline Beecham P.L.C., Brentford Imidazolderivate und deren verwendung als raf kinase inhibitoren
JP2003521543A (ja) 2000-02-07 2003-07-15 アボット ゲーエムベーハー ウント カンパニー カーゲー ２−ベンゾチアゾリル尿素誘導体およびそのプロテインキナーゼ阻害剤としての使用
WO2001072751A1 (en) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
IL154310A0 (en) 2000-08-07 2003-09-17 Neurogen Corp Heterocyclic compounds as ligands of the gabaa receptor
HU229824B1 (en) * 2000-08-10 2014-08-28 Pfizer Italia Srl Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
JP2004521118A (ja) 2001-01-19 2004-07-15 スミスクライン・ビーチャム・コーポレイション 新規化合物およびその使用
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076396A2 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076463A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076984A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
EP1401831A1 (en) 2001-07-03 2004-03-31 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
FR2827861B1 (fr) * 2001-07-27 2004-04-02 Aventis Pharma Sa Derives des indazoles ou des indoles, leur utilisation en medecine humaine et plus particulierement en cancerologie
WO2003024969A1 (en) * 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
ATE420879T1 (de) 2001-09-19 2009-01-15 Aventis Pharma Sa Indolizine als kinaseproteinhemmer
CA2465247C (en) * 2001-10-26 2010-05-18 Aventis Pharmaceuticals Inc. Benzimidazoles and analogues and their use as protein kinases inhibitors
FR2831537B1 (fr) * 2001-10-26 2008-02-29 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation
CA2512546A1 (en) * 2003-01-17 2004-08-05 Merck & Co., Inc. 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CL2004000409A1 (es) * 2003-03-03 2005-01-07 Vertex Pharma Compuestos derivados de 2-(cilo sustituido)-1-(amino u oxi sustituido)-quinazolina, inhibidores de canales ionicos de sodio y calcio dependientes de voltaje; composicion farmaceutica; y uso del compuesto en el tratamiento de dolor agudo, cronico, neu

Also Published As

Publication number Publication date
WO2005007653A3 (fr) 2005-03-24
TW200519110A (en) 2005-06-16
AU2004256945A1 (en) 2005-01-27
EP1646632A2 (fr) 2006-04-19
JP4740841B2 (ja) 2011-08-03
MXPA06000247A (es) 2006-03-30
WO2005007653A2 (fr) 2005-01-27
KR20060054291A (ko) 2006-05-22
US20060199837A1 (en) 2006-09-07
US7435820B2 (en) 2008-10-14
US7109340B2 (en) 2006-09-19
BRPI0412411A (pt) 2006-08-22
JP2007516186A (ja) 2007-06-21
AU2004256945B2 (en) 2009-08-20
CA2532122A1 (fr) 2005-01-27
IL172994A0 (en) 2006-06-11
US20050096345A1 (en) 2005-05-05
EP2251340A1 (fr) 2010-11-17

Similar Documents

Publication Publication Date Title
AR045037A1 (es) Tetrahidro-1h-pirazolo [3,4-c] piridinas sustituidas, composiciones que las contienen y su utilizacion.
DK1288205T3 (da) Nye phenylalanin-derivater
DE60015927D1 (en) Phenylharnstoff und phenylthioharnstoffderivate
BR0214277A (pt) Solvatos de paclitaxel
ES2079534T3 (es) Derivados de polietilenglicol, sus peptidos modificados, metodos para producirlos y uso de los peptidos modificados.
UY26958A1 (es) Nuevos agentes anticolinérgicos que se pueden emplear como medicamentos así como procedimiento para su preparación
DE60033684D1 (de) Phenylalaninderivate
AR012020A1 (es) COMPUESTOS DE N - (TRIAZOLOAZINIL)ARILSULFONAMIDAS, COMPOSICIONES HERBICIDAS QUE LOS COMPRENDEN, MÉTODO PARA CONTROLAR VEGETACIoN INDESEABLE MEDIANTE SU APLICACIoN Y COMPUESTOS INTERMEDIARIOS uTILES COMO INTERMEDIARIOS EN SU PREPARACIoN.
PE20040522A1 (es) Derivados de diarilurea dependientes de la cinasa de proteina
DK1178958T3 (da) N-cyanomethylamider som proteaseinhibitorer
UY26957A1 (es) Nuevos agentes anticolinérgicos que se pueden emplear como medicamentos así como procedimiento para su preparación
EP2615087A3 (en) Phenylalanine derivatives
AR033678A1 (es) Derivados de quinolina, procedimiento para prepararlos, uso de los mismos para la preparacion de medicamentos y los medicamentos que contienen dichos derivados
ATE302775T1 (de) Carbolinderivate
AR053540A1 (es) Derivados de pirrol e imidazol sustituidos,composiciones farmaceuticas que los contienen,y usos como agentes anticancerigenos
FI920023A0 (fi) Heteroarylpiperazinfoereningar som antipsykotiska aemnen.
ATE346067T1 (de) Carbolinderivate
ATE189814T1 (de) Hydroxypyridin-derivate, ihre herstellung und ihre pharmazeutische verwendung
CO6150166A2 (es) Nuevos derivados de [1,3]tiazolo[4,5-d]pirimidin-2-(3h)-amina 5,7-disustituidos y su uso en terapia
AR015233A1 (es) Sulfonamidas, proceso para su preparacion, composiciones farmaceuticas que las comprenden y el uso de las mismas para la fabricacion de medicamentos parael tratamiento de trastornos tromboembolicos.
CO6150165A2 (es) Nevos derivados 5,7-disustituidos de [1,3]tiazolo[4,5-d]pirimidin-2 (3h)-ona y su uso en terapia
AR031837A1 (es) Derivados amino substituidos ramificados de 3-amino-1-fenil-1h [1, 2, 4] triazol, su utilizacion, procedimientos para su preparacion y composiciones farmaceuticas que los contienen
NO971261D0 (no) Kinoksalin-derivater nyttige innen terapi
DE69320705D1 (de) Aminoalkylcarbamatester von Eserolin verwendbar als Inhibitoren von Cholinesteraseaktivität und Verfahren zu deren Herstellung
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate

Legal Events

Date Code Title Description
FB Suspension of granting procedure